

NEULAND LABORATORIES LIMITED

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2016

Amount in Rs Lacs

Sl. No.	Particulars	STANDALONE				CONSOLIDATED		
		Quarter Ended 31.03.2016 (Audited)	Quarter Ended 30.12.2015 (Unaudited)	Quarter Ended 31.03.2015 (Audited)	Year Ended 31.03.2016 (Audited)	Year Ended 31.03.2015 (Audited)	Year Ended 31.03.2016 (Audited)	Year Ended 31.03.2015 (Audited)
1	Income from Operations							
	(a) Net Sales / Income from Operations	12,684.53	11,575.30	12,358.77	48,576.71	44,506.38	48,576.71	44,506.38
	(b) Other Operating Income	819.23	727.68	990.64	2,420.30	2,408.72	2,420.30	2,408.72
	Total Income from Operations (Net)	13,503.76	12,302.98	13,349.36	50,997.01	46,915.10	50,997.01	46,915.10
2	Expenses							
	(a) Consumption of Raw Materials	6,577.83	5,981.31	6,537.73	25,956.67	26,641.89	25,956.67	26,641.89
	(b) Changes in inventories of finished goods and work in process	(526.65)	182.07	677.81	(611.18)	(2,242.89)	(611.18)	(2,242.89)
	(c) Employee Benefit Expense	1,209.90	1,276.03	1,376.03	5,023.10	4,915.80	5,571.80	5,180.94
	(d) Depreciation	411.16	393.31	362.28	1,574.26	1,531.98	1,574.26	1,531.98
	(e) Manufacturing Expenses	1,896.15	1,505.07	1,265.74	6,250.33	5,784.45	6,250.33	5,784.45
	(f) Other Expenses	2,327.44	1,453.12	1,488.40	6,391.12	5,179.41	5,784.84	4,888.79
	Total Expenses	11,895.83	10,790.91	11,707.99	44,584.30	41,810.64	44,526.72	41,785.16
3	Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	1,607.93	1,512.07	1,641.37	6,412.71	5,104.46	6,470.29	5,129.94
4	Other Income	73.10	38.24	76.88	161.91	78.12	177.80	78.37
5	Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)	1,681.03	1,550.31	1,718.25	6,574.62	5,182.58	6,648.09	5,208.31
6	Finance Costs	528.29	636.42	860.37	2,446.60	2,734.86	2,447.80	2,736.13
7	Profit from Ordinary Activities after Finance Costs but before Exceptional Items (5-6)	1,152.74	913.89	857.88	4,128.02	2,447.72	4,200.29	2,472.18
8	Exceptional Items	-	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	1,152.74	913.89	857.88	4,128.02	2,447.72	4,200.29	2,472.18
10	Tax Expense	489.38	286.24	289.19	1,486.54	869.58	1,492.35	878.97
11	Net Profit from Ordinary Activities after Tax (9-10)	663.36	627.65	568.69	2,641.48	1,578.14	2,707.94	1,593.21
12	Extraordinary Items	-	-	-	-	-	-	-
13	Net Profit for the period (11-12)	663.36	627.65	568.69	2,641.48	1,578.14	2,707.94	1,593.21
14	Minority Interest	-	-	-	-	-	(24.51)	(1.48)
15	Net Profit / (Loss) after taxes and minority interest (13-14)	663.36	627.65	568.69	2,641.48	1,578.14	2,732.45	1,594.69
16	Paid-up Equity Share Capital (Face Value Rs 10 per share)	895.39	895.39	895.39	895.39	895.39	895.39	895.39
17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	15,010.28	-	15,165.61
18	Earnings per Share (EPS) (in Rs)							
	(a) Basic (Not Annualized)	7.46	7.07	6.40	29.73	18.47	30.76	18.67
	(b) Diluted (Not Annualized)	7.46	7.07	6.40	29.73	18.47	30.75	18.66

NOTES:

- The above audited financial results have been reviewed by the Audit Committee at their meeting held on May 19, 2016, and approved and taken on record at the Board of Directors meeting held on May 20, 2016.
- The Board of Directors at their meeting held on May 20, 2016 have recommended a dividend of 20% at Rs 2 per share on face value of Rs 10 each aggregating to Rs 213.84 lacs including dividend distribution tax for the financial year 2015-2016.
- EPS for quarter and year ended 31 March, 2015 has been recomputed to adjust for the bonus element of rights issue completed during the financial year 2014-15, in accordance with the provisions of AS 20 - Earnings per Share.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".



5 The statement of assets and liabilities is as follows:

		Amount in Rs Lacs			
SI No	Particulars	STANDALONE		CONSOLIDATED	
		As on 31.03.2016 (Audited)	As on 31.03.2015 (Audited)	As on 31.03.2016 (Audited)	As on 31.03.2015 (Audited)
A	EQUITY AND LIABILITIES				
1	Shareholders' Funds				
	(a) Share Capital	895.39	895.39	895.39	895.39
	(b) Reserves and Surplus	17,521.81	15,087.15	17,768.11	15,242.48
		18,417.20	15,982.54	18,663.50	16,137.87
2	Share Application Money Pending Allotment	-	-	-	-
3	Non-current Liabilities				
	(a) Long-term Borrowings	4,540.00	3,322.15	4,540.00	3,322.15
	(b) Deferred Tax Liability (Net)	1,422.82	1,224.55	1,463.58	1,242.47
	(c) Other Long-term Liabilities	253.00	273.00	253.00	273.00
	(d) Long-term Provisions	684.92	638.48	684.92	638.48
		6,900.74	5,458.18	6,941.50	5,476.10
4	Minority Interest	-	-	-	24.52
5	Current Liabilities				
	(a) Short-term Borrowings	12,362.90	14,579.81	12,362.90	14,579.81
	(b) Trade Payables				
	- Dues to micro and small enterprises	43.78	7.71	43.78	7.71
	- Dues to creditors other than micro and small enterprises	8,308.75	11,168.25	8,332.62	11,173.65
	(c) Other Current Liabilities	5,754.04	3,316.12	5,511.07	3,128.40
	(d) Short-term Provisions	546.72	604.31	549.73	624.84
		27,016.19	29,676.20	26,800.10	29,514.41
	TOTAL	52,334.13	51,116.92	52,405.10	51,152.90
B	ASSETS				
1	Non-current Assets				
	(a) Fixed Assets	17,925.09	16,454.28	17,925.09	16,454.28
	(b) Non-current Investments	754.58	766.80	738.76	738.76
	(c) Long-term Loans and Advances	2,320.67	2,382.91	2,322.67	2,382.91
		21,000.34	19,603.99	20,986.52	19,575.95
2	Current Assets				
	(a) Inventories	12,666.29	11,340.40	12,666.29	11,340.40
	(b) Trade Receivables	11,910.83	12,884.83	11,910.83	12,884.83
	(c) Cash and Bank Balances	904.02	648.66	971.40	698.13
	(d) Short-term Loans and Advances	4,959.00	4,886.64	4,976.41	4,901.19
	(e) Other Current Assets	893.65	1,752.40	893.65	1,752.40
		31,333.79	31,512.93	31,418.58	31,576.95
	TOTAL	52,334.13	51,116.92	52,405.10	51,152.90


6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and subject to audit.

7 The Consolidated financial results include, results for the year ended 31 March 2016 of the following subsidiaries:

- Neuland Laboratories Inc., USA
- Neuland Laboratories KK., Japan
- CATO Research Neuland India Private Limited, India

8 Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to this period's classification.

By Order of the Board
For Neuland Laboratories Limited



Dr. D.R. Rao
Chairman & Managing Director
(DIN 00107737)



Place: Hyderabad
Date: May 20, 2016